Study of the Electrocardiographic Effects of Ponesimod in Healthy Male and Female Subjects
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to demonstrate that therapeutic and supratherapeutic plasma
exposures to ponesimod do not have an effect on cardiac repolarization exceeding the
threshold of regulatory concern as measured by the QTc (interval from beginning of the Q wave
until end of the T wave corrected for heart rate) interval duration after administration of
multiple oral doses of 40 mg and 100 mg to healthy male and female subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Actelion
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Ponesimod